

Viloxazine for attention-deficit hyperactivity disorder: a new formulation for a new indication

Balasundaram MK, Singh A.

Drugs and therapy perspectives

2022; 38(2):77-83

ARTICLE IDENTIFIERS

DOI: 10.1007/s40267-022-00892-z

PMID: unavailable

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: not available

pISSN: 1172-0360

eISSN: 1179-1977

OCLC ID: not available

CONS ID: not available

US National Library of Medicine ID: not available

This article was identified from a query of the SafetyLit database.